Trials / Unknown
UnknownNCT02504229
DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Beijing Biohealthcare Biotechnology Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with S-1 ((Tegafur, Gimeracil, and Oteracil Potassium) and oxaliplatin adjuvant chemotherapy in locally advanced unresectable or metastaticgastric cancer. Half of participants will receive DC-CIK combined with S-1 and oxaliplatin adjuvant chemotherapy,while the other half will receive S-1 and oxaliplatin adjuvant chemotherapy served as controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | autologous dendritic cells co-cultured with cytokine-induced killer cells | |
| DRUG | Gimeracil and Oteracil Porassium Capsules | |
| DRUG | Oxaliplatin |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2018-07-01
- First posted
- 2015-07-21
- Last updated
- 2015-07-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02504229. Inclusion in this directory is not an endorsement.